{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:17:33Z","timestamp":1788585453999,"version":"build-2803163510"},"reference-count":30,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.5551\/jat.65869","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:12:33Z","timestamp":1779142353000},"page":"1157-1179","source":"Crossref","is-referenced-by-count":1,"title":["Hospital Course and Outcomes After Major Bleeding in Patients on Factor Xa Inhibitors in Japan: A Nationwide Observational Study"],"prefix":"10.5551","volume":"33","author":[{"given":"Shun","family":"Kohsaka","sequence":"first","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[{"name":"Fukuoka Neurosurgical Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Hoshino","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Ide","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Wada","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naru","family":"Morita","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Akao M, Ogawa H, Masunaga N, Minami K, Ishigami K, Ikeda S, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Ishii M, Iguchi M, Wada H, Hasegawa K, Tsuji H, Esato M, Abe M. 10-Year Trends of Antithrombotic Therapy Status and Outcomes in Japanese Atrial Fibrillation Patient - The Fushimi AF Registry. Circ J, 2022; 86: 726-736","DOI":"10.1253\/circj.CJ-22-0023"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Troy A, Anderson TS. National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019. JAMA Health Forum, 2021; 2: e211693","DOI":"10.1001\/jamahealthforum.2021.1693"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Joy M, Williams J, Emanuel S, Kar D, Fan X, Delanerolle G, Field BC, Heiss C, Pollock KG, Sandler B, Arora J, Sheppard JP, Feher M, Hobbs FR, de Lusignan S. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019). Heart, 2023; 109: 195-201","DOI":"10.1136\/heartjnl-2022-321377"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, B\u00fcller HR. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost, 2017; 117: 1944-1951","DOI":"10.1160\/TH16-12-0946"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation, 2011; 123: 2363-2372","DOI":"10.1161\/CIRCULATIONAHA.110.004747"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, Jung HS, Washam JB, Welch BG, Zazulia AR, Collins SP. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation, 2017; 135: e604-e633","DOI":"10.1161\/CIR.0000000000000477"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost, 2015; 13: 2012-2020","DOI":"10.1111\/jth.13139"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yanagisawa D, Abe K, Amano H, Komatsuda S, Honda T, Manabe D, Yamamoto H, Kozuma K, Kodashima S, Asaoka Y, Yamamoto T, Tanaka A. Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation. PLoS One, 2021; 16: e0260585","DOI":"10.1371\/journal.pone.0260585"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. J Med Econ, 2017; 20: 1217-1223","DOI":"10.1080\/13696998.2017.1362412"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Marco Garbayo JL, Koninckx Ca\u00f1ada M, P\u00e9rez Castell\u00f3 I, Faus Soler MT, Perea Ribis M. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. European Journal of Hospital Pharmacy, 2019; 26: 106","DOI":"10.1136\/ejhpharm-2017-001390"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol, 2017; 23: 1954-1963","DOI":"10.3748\/wjg.v23.i11.1954"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Brodie MM, Newman JC, Smith T, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med, 2018; 131: 573.e579-573.e515","DOI":"10.1016\/j.amjmed.2017.11.007"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Coleman CI, Dobesh PP, Danese S, Ulloa J, Lovelace B. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future Cardiol, 2021; 17: 127-135","DOI":"10.2217\/fca-2020-0073"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Milling TJ, Jr., Clark CL, Feronti C, Song SS, Torbati SS, Fermann GJ, Weiss J, Patel D. Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. Am J Emerg Med, 2018; 36: 396-402","DOI":"10.1016\/j.ajem.2017.08.042"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pannach S, Goetze J, Marten S, Schreier T, Tittl L, Beyer-Westendorf J. Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. J Gastroenterol, 2017; 52: 1211-1220","DOI":"10.1007\/s00535-017-1320-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Singer AJ, Quinn A, Dasgupta N, Thode HC, Jr. Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non-Vitamin K Antagonist Oral Anticoagulant. J Emerg Med, 2017; 52: 1-7.e1","DOI":"10.1016\/j.jemermed.2016.09.028"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013; 369: 2093-2104","DOI":"10.1056\/NEJMoa1310907"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992","DOI":"10.1056\/NEJMoa1107039"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891","DOI":"10.1056\/NEJMoa1009638"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bialkowski W, Tan S, Mast AE, Kiss JE, Kor D, Gottschall J, Wu Y, Roubinian N, Triulzi D, Kleinman S, Choi Y, Brambilla D, Zimrin A. Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage. Thromb Res, 2020; 185: 109-118","DOI":"10.1016\/j.thromres.2019.11.024"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Cz\u0142onkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, Tanne D, Sandset EC, Tsivgoulis G, Christensen H, Beyer-Westendorf J, Coutinho JM, Crowther M, Verhamme P, Amarenco P, Roine RO, Mikulik R, Lemmens R, Veltkamp R, Middeldorp S, Robinson TG, Milling TJ, Jr., Tedim-Cruz V, Lang W, Himmelmann A, Ladenvall P, Knutsson M, Ekholm E, Law A, Taylor A, Karyakina T, Xu L, Tsiplova K, Poli S, Kallm\u00fcnzer B, Gumbinger C, Shoamanesh A. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med, 2024; 390: 1745-1755","DOI":"10.1056\/NEJMoa2313040"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dobesh PP, Fermann GJ, Christoph MJ, Koch B, Les\u00e9n E, Chen H, Lovelace B, Dettling T, Danese M, Ulloa J, Danese S, Coleman CI. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Research and Practice in Thrombosis and Haemostasis, 2023; 7: 102192","DOI":"10.1016\/j.rpth.2023.102192"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C, Sheth KN, Hanley DF, Ziai WC, Kamel H. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Stroke, 2017; 48: 1594-1600","DOI":"10.1161\/STROKEAHA.116.016327"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Milling TJ, Jr., Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation, 2023; 147: 1026-1038","DOI":"10.1161\/CIRCULATIONAHA.121.057844"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidb\u00fcchel H. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021; 23: 1612-1676","DOI":"10.1093\/europace\/euab065"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024; 149: e1-e156","DOI":"10.1161\/CIR.0000000000001193"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Iwasaki YK, Noda T, Akao M, Fujino T, Hirano T, Inoue K, Kusano K, Nagai T, Satomi K, Shinohara T, Soejima K, Sotomi Y, Suzuki S, Yamane T, Kamakura T, Kato H, Katsume A, Kondo Y, Kuroki K, Makimoto H, Murata H, Oka T, Tanaka N, Ueda N, Yamasaki H, Yamashita S, Yasuoka R, Yodogawa K, Aonuma K, Ikeda T, Minamino T, Mitamura H, Nogami A, Okumura K, Tada H, Kurita T, Shimizu W. JCS\/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias. Circ J, 2025","DOI":"10.1253\/circj.CJ-24-0073"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, Iguchi Y, Shiokawa Y, Takagi Y, Ohtsuki T, Kinouchi H, Okada Y, Takahashi JC, Nakase H, Kakuda W. Japan Stroke Society Guideline 2021 for the Treatment of Stroke. Int J Stroke, 2022; 17: 1039-1049","DOI":"10.1177\/17474930221090347"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sengupta N, Feuerstein JD, Jairath V, Shergill AK, Strate LL, Wong RJ, Wan D. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. Am J Gastroenterol, 2023; 118: 208-231","DOI":"10.14309\/ajg.0000000000002130"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Staerk L, Lip GY, Olesen JB, Fosb\u00f8l EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. Bmj, 2015; 351: h5876","DOI":"10.1136\/bmj.h5876"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_65869\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:52:52Z","timestamp":1788583972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_65869\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65869","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"65869"}}